Khalid El Bairi: My first oral lecture at the Annual Meeting of the ASCO
Khalid El Bairi shared a post on LinkedIn:
“Today marks my first oral lecture at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
I had the pleasure to present the preliminary results of our ONCOTRUST-1 study at this prestigious meeting.
Thanks to the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation for their support to bring researchers from Africa to discuss the global oncology issues in our daily practice and research and to my mentors and collaborators!
Can’t wait for ONCOTRUST-2 study and ASCO25. ”
Source: Khalid El Bairi/LinkedIn
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies. El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023